NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis
Sponsored by AstraZeneca
About this trial
Last updated 17 years ago
Study ID
D9612L00062
Status
Completed
Type
Interventional
Phase
Phase 4
Placebo
No
Accepting
18 to 75 Years
All Sexes
Trial Timing
Ended 21 years ago
What is this trial about?
The purpose of this study is to decide if controlling stomach acid is related to healing of erosive esophagitis after treatment with esomeprazole magnesium (NEXIUM®) 10 mg and 40 mg once daily.
What are the participation requirements?
Inclusion Criteria
* Male or non-pregnant, non-lactating female patients between the ages of 18 and 75 years
* Patients must have moderate to severe erosive esophagitis
Exclusion Criteria
* Significant gastrointestinal bleeding
* Severe heart, lung, liver or kidney disease
* Esophagitis not related to acid reflux